ALS
ASSOCIATION

“ALS progresses too fast for patients to wait years for new treatments. The MINI Act keeps hope alive by:

- Protecting the pipeline of therapies already in development
- Ensuring patients are not left without options
- Giving families more time with their loved ones

Every day matters for someone with ALS, and this legislation recognizes that.”

–Melanie Lendnal, Esq., Senior Vice President, Policy & Advocacy, The ALS Association

American
Brain
Coalition

“Brain diseases and disorders affect millions of Americans every year. From the most common and rare neurological diseases, as well as serious mental illnesses, these conditions represent some of the most urgent public health challenges of our time. Neurological and mental health disorders are now the leading cause of disability worldwide, with a toll that is devastating for patients, families and caregivers. The need for innovation has never been greater. Genetically targeted technologies represent a new frontier in brain health, offering the potential to slow, stop or even prevent conditions that have long gone untreated. The MINI Act protects the investments required to move this science forward, ensuring that promising medications reach patients and help reduce the enormous burden of brain disease on society.”

–Katie Sale, Executive Director, American Brain Coalition

amputee
coalition™

"The MINI Act (H.R. 1672) will incent continued innovation in important GTTs and treatments. We believe this legislation will remove obstacles to future investments in GTTs, which are critical for patients with peripheral artery disease (PAC), a genetic vascular disorder that narrows arteries and reduces blood flow to arms and legs, often resulting in limb loss."

–Shree Thaker, Director of Communications & Partnerships, Amputee Coalition

ABC **Association of Black Cardiologists, Inc.**
Saving the Hearts and Minds of a Diverse America

“Cardiovascular disease continues to disproportionately impact Black communities, and innovation is key to closing that gap. Black Americans are nearly 30% more likely to die from heart disease compared to white Americans, a disparity that has persisted for decades. Genetically targeted technologies hold promise for preventing and treating the conditions that claim far too many lives, including heart failure, stroke and high cholesterol. The MINI Act ensures that lifesaving research does not stall, protecting the progress made in recent years and creating a future where Black patients can access the next generation of treatments. We cannot allow barriers in policy or investment to stand in the way of healthcare.”

–Sara Collins, M.D., FACC, Health Policy Co-Chair, Association of Black Cardiologists, Inc.

FSR
FOUNDATION FOR
SARCOIDOSIS RESEARCH

“Patients with sarcoidosis often endure years of misdiagnosis before finally learning what is wrong. Even then, the treatments available are limited and often come with serious side effects. We need a stronger pipeline of treatments designed specifically for our disease. Legislation like the MINI Act makes that possible by protecting the science and investment that bring hope to patients who have long been overlooked.”

–Tricha Shivas, Chief of Staff and Strategy, Foundation for Sarcoidosis Research (FSR)

GRANGE®

“Families in rural America already drive hours to see specialists or go without advanced care altogether. The Maintaining Investments in New Innovation (MINI) Act is not just legislation for cities and hospitals, it is a commitment that when innovation happens, including breakthroughs in genetically targeted technologies (GTTs), patients in small towns will not be left behind.

For rural communities, this means:

- More treatment options that reach local clinics
- Greater equity between rural and urban health care
- A future where geography no longer dictates access to lifesaving therapies”

–Christine E. Hamp, President, National Grange

"HealthyWomen supports the MINI Act H.R. 1672 to continue investment in research and development for genetically targeted technologies, or GTTs. These treatments address debilitating and rare diseases affecting women, such as:

- Familial Hypercholesterolemia: A common genetic disorder that causes dangerously high levels of low-density lipoprotein (LDL) cholesterol, increasing the risk of early heart disease.
- Primary Hyperoxaluria Type 1: A genetic disorder that causes the liver to produce too much oxalate, leading to recurrent kidney stones, severe abdominal pain and kidney damage.
- Acute Hepatic Porphyria: A group of genetic disorders that affect the body's ability to produce heme, an essential component of red blood cells, causing the buildup of toxic substances in the liver, triggering severe and often unpredictable attacks.

By encouraging medical innovation in GTTs, this legislation not only improves health outcomes for women but also lightens the strain on caregivers, who are, more often than not, women themselves."

– Beth Battaglino, President & CEO, HealthyWomen

"For patients and families affected by genetic disorders, medical innovation isn't just a concept — it's a lifeline. Genetically targeted technologies (GTTs) bring hope for personalized treatments that go beyond managing symptoms to address the root genetic causes. Protecting and advancing GTTs isn't just about scientific progress; it's about delivering life-saving treatments and transforming lives for those who need them most."

–Dominique Lessard, Executive Director, KIF1A.ORG

"Genetically targeted technologies represent a new frontier in the treatment of many of the most devastating diseases, including the leading cause of death for Americans — cardiovascular disease. The MINI Act represents an important step to safeguard investment in these innovative therapies."

–Mandy Sandkuhler, Director, Partnerships and Communications, The Mended Hearts, Inc.

"Heart disease and stroke kill more Americans than any other condition. The MINI Act would protect innovative therapies that could reduce heart attacks, strokes and deaths. It could also help lower spending to treat heart disease by stimulating investment in prevention. The bill is about encouraging investment in prevention. The bill is about encouraging innovation to prevent deaths from leading causes such as heart disease."

–John Clymer, Executive Director, National Forum for Heart Disease & Stroke

"The Latino community faces a multitude of barriers to affordable and culturally competent healthcare services. The MINI Act promises to ensure that our most vulnerable populations have access to our nation's innovative healthcare therapies. It is about equity as much as it is about science."

–Jeanette Contreras, Executive Director, Organization for Latino Health Advocacy

"Our coalition advocates for patients with high cholesterol, elevated lipoprotein(a), and resistant hypertension. Each of these conditions is silent until it becomes deadly. The MINI Act ensures continued innovation so patients can have better tools for prevention and treatment. Progress is the only path to saving lives."

–Ryan Gough, Executive Director, Partnership to Advance Cardiovascular Health

"The stakes are high for patients with vasculitis. Organ damage, disability or even death can result when the right treatment is delayed. Patients can lose kidney function, suffer lung damage or experience strokes before treatment begins. The MINI Act offers a safeguard for continued research and development, ensuring treatments reach patients faster and giving our community the chance to prevent irreversible harm. Every day without effective treatment is a day a patient risks permanent organ damage, and this legislation helps change that reality."

–Joyce Kullman, Executive Director, Vasculitis Foundation